Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Repeat RSV Maternal Vaccination
NCT05229068Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RSVPreF3 in respiratory syncytial virus infection (RSV), sponsored by GSK. Planned start Mar 2022; status: withdrawn.
02
Drugs
RSVPreF3
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05229068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229068.